Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]

东诚药业（002675）公告，控股子公司蓝纳成组织开展的氟[18F]思睿肽注射液III期临床试验已完成全 部488例受试者入组。该药物为靶向PSMA的放射性体内诊断药物，适用于前列腺癌患者的正电子发射 断层扫描(PET)成像。目前国内未有同类产品上市，国外已有同类产品上市，根据Lantheus公司的2024 年度报告显示，其产品18F-PSMA诊断药PYLARIFY，2024年实现销售收入11亿美元。氟[18F]思睿肽注 射液项目累计已投入研发费用约1.19亿元。 ...

烟台东诚药业集团股份有限公司 证券代码：002675 证券简称：东诚药业 公告编号：2025-030 二、药物的其他情况 关于氟[ 18F]思睿肽注射液 III 期临床试验完成全部受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，烟台东诚药业集团股份有限公司（以下简称"公司"或"上市公司"）控 股子公司烟台蓝纳成生物技术股份有限公司（以下简称"蓝纳成"）组织开展的氟[ 18F] 思睿肽注射液 III 期临床试验，目前已完成全部 488 例受试者入组。现将相关情况公 告如下： | 药物名称 | 18F]思睿肽注射液 氟[ | | | --- | --- | --- | | 剂型 | 注射剂 | | | 注册分类 | 化药Ⅰ类新药 | | | 适应症 | 适应症一 | 适应症二 | | 伦理审查意见号 | 2023BJYYEC-367-02 | 2023BJYYEC-368-02 | | 具体适应症内容 | 评 价 氟 18F] 思 睿 肽 注 射 液 [ | 评 价 氟 18F] 思 睿 肽 注 射 液 [ | | | PET/CT 显像在 ...

Group 1 - The cell immunotherapy concept index rose by 1.25%, ranking 6th among concept sectors, with 29 stocks increasing in value [1][2] - Notable gainers included Ruizhi Pharmaceutical with a 20% limit up, Hainan Haiyao at limit up, and Shutaishen, Guanhao Biological, and Fosun Pharma with increases of 15.02%, 8.88%, and 5.23% respectively [1][6] - The sector experienced a net outflow of 266 million yuan, with 20 stocks seeing net inflows, and 8 stocks receiving over 10 million yuan in net inflows, led by Hainan Haiyao with a net inflow of 144 million yuan [2][3] Group 2 - Hainan Haiyao, Anke Bio, and Dongcheng Pharmaceutical had the highest net inflow ratios at 35.56%, 5.52%, and 5.27% respectively [3][4] - The top stocks by net inflow included Hainan Haiyao, Fosun Pharma, Ruizhi Pharmaceutical, and Zhaoyan New Drug, with net inflows of 144 million yuan, 54.52 million yuan, 34.78 million yuan, and 31.86 million yuan respectively [2][3] - Stocks with significant declines included Xue Rong Biological, Saifutian, and Jinchang Protein, with decreases of 4.23%, 2.74%, and 2.61% respectively [1][5]

Group 1 - Guangdian Electric's wholly-owned subsidiary plans to sell 5.91% stake in Shanghai Winshun Electric Technology Co., Ltd. to Yapp Automotive Parts Co., Ltd. for 62.63 million yuan, aiming to optimize asset structure [1] - Anhui Natural Gas received approval for the registration of 500 million yuan short-term financing bonds and 600 million yuan medium-term notes, valid for two years [1] - Kirin Security received government subsidies totaling 6.48 million yuan, which are related to revenue [2] Group 2 - Junshi Biosciences received approval for two new indications for its self-developed drug, Oncorhynchus monoclonal antibody injection, targeting adult patients with heterozygous familial hypercholesterolemia and non-familial hypercholesterolemia [3] - China Resources Double Crane's subsidiary passed GMP compliance inspection for small and large volume injection production lines [4] - Nanjing Public Utilities' board approved the absorption and merger of its wholly-owned subsidiary, Nanjing Jinguang Industry Co., Ltd. [7] Group 3 - Boya Bio received drug registration certificate for human immunoglobulin (pH4) in the Dominican Republic, valid until August 12, 2029 [8] - Jizhi Co. announced that its controlling shareholder and actual controller committed not to reduce their shareholdings until December 31, 2025 [9] - Yuhua Tian won a bid for the integrated urban management project in Lanzhou City, with a total service subsidy of 353 million yuan [10] Group 4 - Anke Rui obtained five invention patent certificates related to various energy management and control technologies [11] - Kebo Da's wholly-owned subsidiary plans to acquire 100% of Czech IMI Company for approximately 9.43 million euros to enhance global production layout [13] - Yantian Port announced a cash dividend of 1.30 yuan per 10 shares, totaling 676 million yuan [14] Group 5 - Huawang Technology plans to distribute a cash dividend of 0.45 yuan per share and a capital reserve increase of 0.20 shares per share [15] - Kabe Yi established a wholly-owned subsidiary in Japan to enhance its business layout [16] - Dongcheng Pharmaceutical's subsidiary received approval for the marketing of sodium fluoride injection, a PET radiopharmaceutical [18] Group 6 - Huaxin New Materials' subsidiary received two utility model patent certificates for innovative devices [19] - Lingang Steel's new 2290 cubic meter blast furnace has been successfully put into operation [21] - Xinlitai received drug registration certificate for Sacubitril/Valsartan tablets, the first of its kind in China [23] Group 7 - Aike Co.'s subsidiary received project designation notices from multiple clients for electric drive platform components [25] - Tonghe Pharmaceutical received drug registration certificate for Apixaban in South Korea [26] - Junting Hotel signed a cooperation agreement with Choice Hotels for exclusive brand usage in mainland China [28] Group 8 - Guangdong Hongtu plans to establish a wholly-owned subsidiary in Zhengzhou to enhance market layout [30] - Yuheng Pharmaceutical signed a joint promotion agreement for Pemafibrate tablets with Xinghe Pharmaceutical [31] - Chongqing Steel terminated the absorption and merger of its wholly-owned subsidiary, citing strategic advantages of independent operation [33] Group 9 - Jihong Co. announced the listing of its H-shares on the Hong Kong Stock Exchange [34] - Deshi Co. announced plans for shareholders to reduce their holdings by up to 0.3% [36] - Xinhai Medical's subsidiary received medical device registration for a dialysis fluid filter [42]

二、药物的其他情况 关于氟[ 18F]化钠注射液获得国家药品监督管理局 上市许可的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，烟台东诚药业集团股份有限公司（以下简称"公司"）全资子公司南 京江原安迪科正电子研究发展有限公司（以下简称"安迪科"）收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的氟[ 18F]化钠注射液《药品注册证 书》，氟[ 18F]化钠注射液通过药品上市许可申请，可生产销售。 现将相关情况公告如下： | 药品名称 | 氟[ 18F]化钠注射液 | | | --- | --- | --- | | 受理号 | CYHS2302776 | | | 剂型 | 注射剂 | | | 申请事项 | 药品注册（境内生产） | | | 规格 | 370~7400MBq/ml | | | 注册分类 | 化学药品 3 类 | | | 包装规格 | 每个铅屏蔽容器放置 瓶 1 | | | 处方药/非处方药 | 处方药 | | | 上市许可持有人 | 名称：南京江原安迪科正电子研究发展有限公司 | | | | 地址：南京市江宁区科学园乾德路 ...

Summary of Key Points Core Viewpoint - Dongcheng Pharmaceutical (002675) has announced a cash dividend distribution plan for the year 2024, which is expected to enhance shareholder value and reflects the company's ongoing commitment to returning profits to its investors [1][2]. Company Announcement Summary - The company will distribute a cash dividend of RMB 0.30 per 10 shares, totaling RMB 24,737,871.15, based on a total share capital of 824,595,705 shares as of December 31, 2024 [2]. - After the profit distribution, the remaining undistributed profits amount to RMB 1,338,768,971.39, which will be carried forward to the next fiscal year [2]. - The dividend distribution plan has been approved by the company's 2024 annual general meeting and will be executed without any changes to the total share capital [2]. - Key dates include the equity registration date on May 26, 2025, and the ex-dividend date on May 27, 2025 [2]. - Cash dividends for A-share shareholders will be directly credited to their accounts through their securities companies on the ex-dividend date [2].

证券代码：002675 证券简称：东诚药业 公告编号：2025-028 烟台东诚药业集团股份有限公司 2024年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、烟台东诚药业集团股份有限公司（以下简称"公司"或"本公司"）2024 年度权益分派方案为：以 2024 年 12 月 31 日的总股本 824,595,705 股为基数， 向全体股东按每 10 股派发现金股利人民币 0.30 元（含税），共计派发现金人民 币 24,737,871.15 元。利润分配后，剩余未分配利润（合并）1,338,768,971.39 元结转下一年度。若在上述分配方案披露后至实施期间，公司总股本因可转债转 股、股份回购、股权激励行权、再融资新增股份上市等原因而发生变化的，分配 比例将按分派总额不变的原则相应调整。 2、自上述分配方案披露至实施期间公司股本总额没有发生变化。 3、本次实施的分配方案与公司 2024 年度股东大会审议通过的分配方案一致。 本次权益分派股权登记日为：2025 年 5 月 26 日，除权除息日为：2025 年 5 月 27 ...

Core Viewpoint - The legal opinion issued by Beijing Zhonglun Law Firm confirms that the convening, holding procedures, qualifications of the convenor and attendees, voting procedures, and voting results of the 2025 first extraordinary general meeting of shareholders of Yantai Dongcheng Pharmaceutical Group Co., Ltd. are in compliance with relevant laws and regulations as well as the company's articles of association [12][23]. Group 1: Meeting Procedures - The board of directors approved the proposal to convene the extraordinary general meeting on April 29, 2025, and the notice was published on April 30, 2025, detailing the meeting time, location, participants, and agenda [2][17]. - The meeting was held on May 15, 2025, at 14:50 at the company's conference room, consistent with the notice [3][16]. - The network voting was conducted from 9:15 to 15:00 on the same day, allowing shareholders to participate remotely [3][16]. Group 2: Attendance and Voting - A total of 137 shareholders and representatives attended the meeting, representing 357,008,886 shares, which is 43.2950% of the total shares [19]. - Among the attendees, 3 shareholders represented 231,250,495 shares (28.0441%), while 134 participated via online voting, representing 125,758,391 shares (15.2509%) [19]. - The meeting included 133 small investors, representing 81,509,055 shares (9.8847%) [19]. Group 3: Voting Results - The proposal regarding the purchase of minority shareholder equity in a subsidiary was approved, with 125,664,991 shares voting in favor (99.9257% of non-related shareholders) [8][21]. - Small shareholders voted 81,415,655 shares in favor (99.8854% of non-related small shareholders) [9][22]. - No new proposals were raised during the meeting, and the voting process was conducted without objections [6][7]. Group 4: Legal Opinion - The legal opinion confirms that all aspects of the meeting, including convening, attendance, and voting, were conducted legally and effectively [12][23].

证券代码：002675 证券简称：东诚药业 公告编号：2025-027 烟台东诚药业集团股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 2.本次股东大会未涉及变更前次股东大会决议。 一、会议召开情况 （一）召开时间： 现场会议时间：2025年5月15日（星期四）14:50； 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025年5月15日9:15－9:25，9:30－11:30，13:00－15:00；通过深圳证券交易所 互联网投票系统投票的具体时间为：2025年5月15日9:15-15:00期间的任意时间。 （二）现场会议地点：烟台经济技术开发区长白山路7号公司会议室； （六）本次股东大会的召集、召开程序符合《公司法》《上市公司股东大会 规则》等法律、法规、规范性文件和《公司章程》的规定。 二、会议出席情况 参加本次会议的股东及股东代理人共137人，代表公司有表决权的股份 357,008,886股，占公司有表决权股份总数的43.2950%。其中：1、出席本次现场 会议的股东及股东代 ...